AI Engines For more Details: Perplexity Kagi Labs You
Skin Health: Panthenol is widely used in skincare products, including creams, lotions, ointments, and moisturizers, due to its ability to attract and retain moisture in the skin. It helps hydrate the skin, improve its elasticity, and promote healing of dry, irritated, or damaged skin.
Wound Healing: Panthenol is known for its wound-healing properties. When applied topically, it can accelerate the healing process of minor wounds, cuts, abrasions, and burns. Panthenol promotes skin regeneration and tissue repair by stimulating cell proliferation and collagen synthesis.
Sunburn Relief: Panthenol is often included in after-sun products and sunburn treatments due to its soothing and anti-inflammatory effects on sun-damaged skin. It helps reduce redness, irritation, and discomfort associated with sunburns.
Diaper Rash: Panthenol-containing creams or ointments are commonly used to alleviate diaper rash in infants. Its moisturizing and protective properties help soothe irritated skin and promote healing in the diaper area.
Hair Care: Panthenol is also used in hair care products such as shampoos, conditioners, and styling products. It helps improve the texture, strength, and elasticity of hair by moisturizing and conditioning the hair shaft. Panthenol can also enhance hair shine and manageability.
Anti-inflammatory Effects: Panthenol exhibits mild anti-inflammatory effects, making it beneficial for soothing and calming inflamed or irritated skin conditions, such as eczema, dermatitis, and insect bites.
Sensitive Skin: Due to its gentle nature, panthenol is suitable for individuals with sensitive or allergy-prone skin. It is well-tolerated and rarely causes allergic reactions or irritation.
Preventive Care: Panthenol-containing skincare products can also be used for preventive care to maintain skin hydration and integrity, especially in harsh environmental conditions or during exposure to irritants.
Absorption: When applied topically, panthenol is readily absorbed by the skin and converted into pantothenic acid, which is a component of coenzyme A involved in various metabolic processes. This conversion enhances its moisturizing and healing effects on the skin.
Pregnancy and Breastfeeding: Panthenol is generally considered safe for use during pregnancy and breastfeeding when applied topically to the skin. However, it's essential to consult with a healthcare professional before using any skincare products during pregnancy or while breastfeeding.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 0.3 | 0.3 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.4 | -0.33 |
| Allergies | 0.4 | 0.4 | 0 |
| Allergy to milk products | 0 | 0.3 | 0 |
| Alzheimer's disease | 0.4 | 0.6 | -0.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0 | 0 |
| Ankylosing spondylitis | 0.6 | 0.3 | 1 |
| Anorexia Nervosa | 0.3 | 0.3 | 0 |
| Asthma | 0.6 | 0.4 | 0.5 |
| Atherosclerosis | 0.3 | 0 | 0 |
| Atrial fibrillation | 0.6 | 0.3 | 1 |
| Autism | 0.4 | 0.8 | -1 |
| Autoimmune Disease | 0.3 | 0.3 | 0 |
| Brain Trauma | 0.3 | 0.3 | 0 |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.4 | -0.4 | |
| Carcinoma | 0.3 | 0.3 | 0 |
| Celiac Disease | 0.7 | -0.7 | |
| Cerebral Palsy | 0.3 | 0.3 | |
| Chronic Fatigue Syndrome | 0.3 | 0.3 | 0 |
| Chronic Kidney Disease | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | -0.3 | |
| Chronic Urticaria (Hives) | 0 | 0 | |
| Cognitive Function | 0.3 | 0.3 | 0 |
| Colorectal Cancer | 1 | 0.3 | 2.33 |
| Constipation | 0.3 | 0.3 | |
| COVID-19 | 0.4 | 0.5 | -0.25 |
| Crohn's Disease | 0.3 | 0.8 | -1.67 |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0 | 0 | |
| Depression | 1.3 | 1.3 | 0 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.3 | -0.3 | |
| Endometriosis | 0.3 | 0.3 | 0 |
| Epilepsy | 0.3 | 0.4 | -0.33 |
| erectile dysfunction | 0.3 | -0.3 | |
| Fibromyalgia | 0.3 | 0.3 | 0 |
| Functional constipation / chronic idiopathic constipation | 0.6 | 0.3 | 1 |
| gallstone disease (gsd) | 0.3 | -0.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 0 | 0.4 | 0 |
| Gout | 0 | 0 | 0 |
| Graves' disease | 0.3 | 0.3 | 0 |
| Gulf War Syndrome | 0.4 | -0.4 | |
| Hashimoto's thyroiditis | 0.3 | 0.6 | -1 |
| Heart Failure | 0.1 | 0.3 | -2 |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.3 | -0.3 | |
| hypercholesterolemia (High Cholesterol) | 0 | 0 | |
| hyperglycemia | 0.6 | 0.4 | 0.5 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypertension (High Blood Pressure | 0.6 | 0.5 | 0.2 |
| Hypothyroidism | 0 | 0.3 | 0 |
| Hypoxia | 0.3 | 0.3 | 0 |
| IgA nephropathy (IgAN) | 0.4 | -0.4 | |
| Inflammatory Bowel Disease | 0.3 | 0.7 | -1.33 |
| Insomnia | 0.4 | -0.4 | |
| Intracranial aneurysms | 0.3 | -0.3 | |
| Irritable Bowel Syndrome | 0.4 | 0.6 | -0.5 |
| ischemic stroke | 0.4 | 0.4 | |
| Liver Cirrhosis | 0.3 | 1 | -2.33 |
| Long COVID | 0.6 | 0.8 | -0.33 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0 | 0 | |
| Mast Cell Issues / mastitis | 0.3 | -0.3 | |
| ME/CFS with IBS | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.3 | -0.3 | |
| Menopause | 0.1 | 0 | 0 |
| Metabolic Syndrome | 0.3 | 0.8 | -1.67 |
| Mood Disorders | 1.3 | 0.7 | 0.86 |
| multiple chemical sensitivity [MCS] | 0 | 0 | |
| Multiple Sclerosis | 0.4 | 0.4 | 0 |
| Multiple system atrophy (MSA) | 0.1 | 0.3 | -2 |
| neuropathic pain | 0.7 | -0.7 | |
| Neuropathy (all types) | 0 | 0 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | 0.7 | -1.33 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 1.6 | 1.8 | -0.13 |
| obsessive-compulsive disorder | 0.3 | 0.3 | 0 |
| Osteoarthritis | 0.3 | -0.3 | |
| Osteoporosis | 0 | 0 | |
| Parkinson's Disease | 1 | 0.6 | 0.67 |
| Polycystic ovary syndrome | 0.3 | 0.3 | 0 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| Psoriasis | 0.3 | 0 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.7 | 0.3 | 1.33 |
| Rosacea | 0.3 | 0.3 | 0 |
| Schizophrenia | 0.7 | 0.6 | 0.17 |
| scoliosis | 0.1 | -0.1 | |
| Sjögren syndrome | 0.3 | -0.3 | |
| Sleep Apnea | 0.6 | 0.6 | |
| Slow gastric motility / Gastroparesis | 0.3 | -0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | -0.1 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.3 | 0 |
| Systemic Lupus Erythematosus | 0.6 | -0.6 | |
| Tic Disorder | 0.3 | -0.3 | |
| Tourette syndrome | 0 | 0 | |
| Type 1 Diabetes | 0 | 1 | 0 |
| Type 2 Diabetes | 0.3 | 0.7 | -1.33 |
| Ulcerative colitis | 0.6 | 0.4 | 0.5 |
| Unhealthy Ageing | 0.3 | -0.3 | |
| Vitiligo | 0.6 | 0.3 | 1 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
